Management of access to branded psychotropic medications in private health plans

Clinical Therapeutics

Volumn 29, Issue 2, 2007, Pages 371-380

  Hodgkin, Dominic ^a   Horgan, Constance M ^a   Garnick, Deborah W ^a   Len Merrick, Elizabeth ^a   Volpe Vartanian, Joanna ^a  

^a BRANDEIS UNIVERSITY   (United States)

Author keywords

copayment; formulary; pharmacy benefits; prior authorization; psychotropic medications

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATOMOXETINE; CITALOPRAM; ESCITALOPRAM; METHYLPHENIDATE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SERTRALINE; ZIPRASIDONE;

ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DEPRESSION; DRUG COST; HEALTH CARE ACCESS; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH SURVEY; HUMAN; PRIVATE HEALTH INSURANCE; PSYCHOSIS;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COST SHARING; DATA COLLECTION; DRUG COSTS; DRUGS, GENERIC; FORMULARIES; HEALTH SERVICES ACCESSIBILITY; HEALTH SURVEYS; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MODELS, STATISTICAL; PATIENT COMPLIANCE; PRIVATE SECTOR; PSYCHOTROPIC DRUGS;

EID: 34247514041     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.02.011     Document Type: Article

References (28)

1. Zuvekas S.H. Prescription drugs and the changing patterns of treatment for mental disorders, 1996-2001. Health Aff (Millwood) 24 (2005) 195-205
2. web exclusive W5-133-142. Mark T.L., Coffey R.M., Vandivort-Warren R., et al. US spendinig for mental health and substance abuse treatment, 1991-2001. Health Aff (Millwood) (2005)
3. Frank R.G., Conti R.W., and Goldman H.H. Mental health policy and psychotropic drugs. Milbank Q. 83 (2005) 271-298
4. Employer health benefits 2005: Anational sumey (2005), Kaiser Family Foundation, Washington, DC. http://www.kff.org/insurance/7315/index.cfm
5. Huskamp H.A. Managing psychotropic drug costs: Will formuloriess work?. Health Aff (Millwood) 22 (2003) 84-96
6. Koyanagi C., and Sernansky R. Medicaid policies on outpatient prescription psychiatric drugs: A survey (2003), Bazelon Center for Mental Health Law, Washington, DC
7. Simon G. Choosing a first-line antidepressant: Equal on average does not mean equal for everyone. JAMA 286 (2001) 3003-3004
8. Simon G.E., VonKorff M., Heiligenstein J.H., et al. Initial anti-depressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressant. JAMA 275 (1996) 1897-1902
9. Thase M.E., Blomgren S.L., Birkett M.A., et al. Fluoxetine treatment of patients with major dpressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 58 (1997) 16-21
10. Gelenberg A.J., and Pies R. Matching the bipolar patient and the mood stabilizer. Ann Clin Psychiatry 15 (2003) 203-216
11. Bull S.A., Hunkeler E.M., Lee J.Y., et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother 36 (2002) 578-584
12. Perkins D.O. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 63 (2002) 1121-1128
13. Briesacher B., Kamal-Bahl S., Hochberg M., et al. Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drug. Arch Intern Med. 164 (2004) 1679-1684
14. Fainnan K.A., Mother B.R., and Henderson R.R. Retrosprctive, long-term follow-up study of the effect of a three-tier preschpxiondmg copaymenrsysem on pharmaceutical and other medical utilization and costs. Clin Ther. 23 (2003) 3147-3161
15. Huskamp H.A., Deverka P.A., Epstein A.M., et al. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 349 (2003) 2224-2232
16. [published correction appears in JAMA, 2002; 288:2409]. Joyce G.F., Escarce J.J., Solomon M.D., and Goldman D.P. Employer drug benefit plans and spending on pre scription drugs. JAMA 288 (2002) 1733-1739
17. Huskamp H.A., Deverka P.A., Epstein A.M., et al. Impact of 3-tier formularies on drug treatment of attention deficit/hyperactivity disorder in children Arch Gen Schildren. Arch Gen Psychiatry. 62 (2005) 435-441
18. Landsman P.G., Yu W., Liu X., et al. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. J Am Manage Care 11 (2005) 621-628
19. Gleason P.P., Gunderson B.W., and Gericke K.R. Are incentive-based formularies inversely associated with drug utilization in managed care?. Ann Pharmacother 39 (2005) 339-345
20. Gabel J., Claxon G., Gil I., et al. Health benefits in 2005: Premium increases slow down, coverage continues to erode. Health Aff (Millwood) 24 (2005) 1273-1280
21. Kemper P., Blumenthal D., Corrigan J.M., et al. The design of the Community Tracking Study: A longitudinal study of health system change and its effects on people. Inquiry 33 (1996) 195-206
22. US Food and Drug Administration. Electronic Orange Book approved drug products with therapeutic equivalence evaluations (February 24, 2006). http://www.fda.gov/cder/ob/default.htm
23. Rush A.J., Trivedi M.H., Wisniewski S.R., et al., STAR*D Study Team. Bupropion-SR, sertraline, on venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 354 (2006) 1231-1242
24. Davis J.M., and Chen N. Choice of maintenance medication for schizophrenia. J Clin Psychiatry. 64 Supp 16 (2003) 24-33
25. Pelham W.E., Gnagy E.M., Burrow-Maclean L., et al. Once-a-day concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural setting. Pediatrics 107 (2001) E105
26. Express Scripts. Drug Trend Report 2003 (2004), Maryland Heightn Mo
27. Robinson J.C. The end of managed care. JAMA 285 (2001) 2622-2628
28. Reicher S., Simon T., and Halm E.A. Physicians' attitudes about prescribing and knowledge of the cost of common medications. Arch Intern Med. 160 (2000) 2799-2803